Japan's Western M&A Targets Drying Up? Astellas-OSI Bid Underscores Hostile Pressures - BIO Asia
This article was originally published in PharmAsia News
TOKYO - Japan's leading pharma companies have made a number of high profile M&A moves in the past two years, and there are no signs that they are done with their pursuits. However, the number of attractive biotechs at the right stage of growth and value has decreased drastically
You may also be interested in...
Genzyme depicts itself as the picture of health with enzyme replacement therapy business returning to normal after manufacturing woes.
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17, 2010 with a definitive merger agreement that has the unanimous support of both companies' boards. The victory cost $4 billion, about $500 million more than the original hostile bid which Astellas launched in late February ("The Pink Sheet" DAILY, March 1, 2010)
Japan's largest drug company Takeda hopes to minimize the impact of looming patent expirations in the U.S. by relying on mergers and acquisitions to increase its pipeline and extend its territory coverage, especially in emerging countries